Fluciclovine F-18
Information about the radiopharmaceutical Fluciclovine F-18
| Fluciclovine F-18 | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | Intravenous |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 902143-01-5 |
| PubChem | 71301030 |
| DrugBank | DB05283 |
| ChemSpider | 29341430 |
| KEGG | D10868 |
Fluciclovine F-18 is a radiopharmaceutical used in positron emission tomography (PET) imaging. It is primarily utilized for the detection of recurrent prostate cancer in patients with elevated prostate-specific antigen (PSA) levels following prior treatment.
Mechanism of Action[edit | edit source]
Fluciclovine F-18 is a synthetic amino acid analog that is taken up by amino acid transporters overexpressed in prostate cancer cells. The radiolabeled compound emits positrons that are detected by PET imaging, allowing for the visualization of cancerous lesions.
Clinical Use[edit | edit source]
Fluciclovine F-18 is indicated for use in patients with suspected prostate cancer recurrence based on elevated PSA levels. It provides a non-invasive method to localize recurrent disease, which can guide further therapeutic interventions.
Administration[edit | edit source]
The compound is administered via intravenous injection. The recommended dose is typically based on the patient's body weight and the specific imaging protocol.
Safety and Precautions[edit | edit source]
As with any radiopharmaceutical, there are potential risks associated with exposure to radiation. Patients should be informed of these risks, and the use of Fluciclovine F-18 should be justified by the potential diagnostic benefits.
Regulatory Status[edit | edit source]
Fluciclovine F-18 is approved by the Food and Drug Administration (FDA) for use in the United States. It is marketed under the trade name Axumin.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
